RUNX1 and acute myeloid leukemia: Taken together, the RUNX1/ETO-supported expression of drivers of G1 cell-cycle progression is causatively linked with strong single-agent activity of palbociclib against t(8;21) AML in vitro and in vivo (Figure 7L).